ISIS 2503
- Generic Name
- ISIS 2503
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 149957-14-2
- Unique Ingredient Identifier
- I444I66XWH
- Background
ISIS 2503 is under investigation in clinical trial NCT00004193 (ISIS 2503 in Treating Patients With Metastatic And/or Locally Recurrent Colorectal Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
ISIS 2503 in Treating Patients With Metastatic and/or Locally Recurrent Colorectal Cancer
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2013-04-12
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 25
- Registration Number
- NCT00004193
- Locations
- 🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2011-01-04
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 4
- Registration Number
- NCT00005594
- Locations
- 🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
Gemcitabine and ISIS 2503 in Treating Patients With Advanced or Metastatic Cancer of the Pancreas
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-03-08
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 48
- Registration Number
- NCT00006467
- Locations
- 🇺🇸
CCOP - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸Siouxland Hematology-Oncology, Sioux City, Iowa, United States
🇺🇸CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath